Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have advanced non-squamous non-small cell lung cancer (a specific type of lung cancer) that has either spread to other parts of the body (Stage IV) or has come back after earlier treatment that was intended to cure it
- People whose cancer was previously treated with 4 to 6 cycles of a specific combination of chemotherapy and immunotherapy drugs (Pemetrexed, Carboplatin, and Pembrolizumab), and whose cancer then continued to grow after at least 18 weeks of ongoing maintenance treatment with some or all of those drugs
- People with a performance status score of 0 or 1, meaning they are fully active or able to carry out light activity (confirm with trial site)
Who may not be able to join:
- People whose lung cancer has a specific genetic change (called a driver mutation) that could be treated with targeted therapy drugs
- People who currently have another active cancer that requires ongoing treatment
- People experiencing moderate or severe nerve damage causing sensory problems (such as numbness or tingling), rated Grade 2 or higher
- People who have brain metastases (cancer that has spread to the brain) that have not yet been treated
- People with a history of bleeding disorders, or those who have coughed up more than half a teaspoon of blood in the past two months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Melina Marmarelis, MD, Abramson Cancer Center at Penn Medicine
Phone: 215-220-9703
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To estimate overall response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.